^
Association details:
| Biomarker: | ARID1A mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | ceralasertib (AZD6738) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
512O - Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies
Published date:
09/13/2021
Excerpt:
Of screened pts whose tumors harbored pathogenic mutations in ARID1A, 28/42 (67%) had BAF250a loss of expression by IHC. Twenty pts were enrolled (10/cohort). The median number of lines of prior therapy was 2 (range 0 – 5). In Cohort 1, the ORR was 20%. Two complete responses (CRs) were observed, and both pts remain on treatment for 19.8+ and 14.7+ months duration, respectively, with ongoing CRs....We observed anti-tumor activity with single agent ceralasertib in ARID1A-deficient solid tumors...
Trial ID:
